CN1572309A - Novel Chinese traditional medicine preparation of WuBei Powder for suspension and its preparation method - Google Patents
Novel Chinese traditional medicine preparation of WuBei Powder for suspension and its preparation method Download PDFInfo
- Publication number
- CN1572309A CN1572309A CN 200410008194 CN200410008194A CN1572309A CN 1572309 A CN1572309 A CN 1572309A CN 200410008194 CN200410008194 CN 200410008194 CN 200410008194 A CN200410008194 A CN 200410008194A CN 1572309 A CN1572309 A CN 1572309A
- Authority
- CN
- China
- Prior art keywords
- preparation
- wubei
- mixing
- dry mixed
- mixed suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a novel Chinese traditional medicine preparation, concretely relates to a WuBei dry mixed suspension preparation and its preparation method. The preparation conquers the fault of the existing WuBei powder preparation in market, has the advantages of convenient in taken and use, enlarged surface, and best medical effect for curing diseases such as stomach-ache pantothenic acid, stomach, duodenal ulcer, ileotyphus haemorrhage and chronic gastritis. There in no dry mixed suspension preparation in current domestic Chinese medicine market, the invention is a pioneer in Chinese medicine. The invention provides a method for preparing the WuBei dry mixed suspension preparation.
Description
Technical field:
The present invention relates to a kind of new product of Chinese medicine, specifically relate to a kind of WuBei dry mixed suspension and preparation method thereof.
Background technology:
Dried mixed suspension preparation is a kind of comparatively advanced dosage form, its technology and preparation have obtained using widely in chemical drugs, but on Chinese patent medicine market, also there is not at present relevant report, Medicinal powder of cuttlefish and firtillary bulb dry suspension of the present invention is a domestic initiation, and the present invention provides a kind of preparation method of Medicinal powder of cuttlefish and firtillary bulb dry suspension simultaneously, to the variation of later Chinese patent medicine dosage form, modernization has reference value, is significant.
The WuBei dry mixed suspension prescription is: Endoconcha Sepiae 850g, Bulbus Fritillariae Thunbergii 150g, Oleum Citri Reticulatae 1.5g function: relieving gastric hyperacidity to alleviate stomachache, astringing to arrest bleeding.Cure mainly: stomachache pantothenic acid, stomach, duodenal ulcer.It is hemorrhage also to can be used for ileotyphus, diseases such as chronic gastritis.The prescription source is one one of the Pharmacopoeia of the People's Republic of China, and this side has: 1, promote ulcer surface healing effect; 2, antacid effect originally can obviously suppress the gastric juice digesting protein and absorb pepsin, also has gastric acid inhibitory to secrete the general action of similar anticholinergic neurologic agent.
Should have powder, capsule, three kinds of dosage forms of granule in the side in the market:
Powder: the pharmacopeia kind, one nine seven seven editions, one nine nine zero editions, one nine nine five editions, 2000 editions one one of pharmacopeia are all recorded.Recorded 26 years continuously by state-promulgated pharmacopoeia at present, through for many years clinical practice checking, determined curative effect, the kind that has no side effect.
Capsule: Duotai Pharmaceutical Co., Ltd., Chongqing, 0.5g/ grain, 6/time, 3 times/day.
Granule: 4g/ bag, 3 bag/days, drinking-water is swallowed.
These three kinds of dosage forms are all national epigastric pain nonprescription drugs
Yet these three kinds of dosage forms are taken equal inconvenience, and powder, granule granule are too thick, and grains of sand sense is serious, takes inconvenience, and surface area is little simultaneously, and coverage rate is narrow, can not form the effective protecting film of one deck, and ulcer surface adequately protects; Capsule is taken six at every turn, and the patient takes, carries inconvenience, can not form the effective protecting film of one deck simultaneously, and ulcer surface adequately protects.Yet gastric ulcer is a frequently-occurring disease, commonly encountered diseases, basically each adult has certain gastric ulcer, therefore this side developed one and can be fit to market and patient demand, and the novel form of taking convenience just seems very urgent that WuBei dry mixed suspension of the present invention has just in time solved this problem.The latest domestic technology has been adopted in the invention of this dry suspension, and on the domestic market, Chinese patent medicine is gone back the kind of neither one dry suspension so far, and this project belongs to a kind of innovation on Chinese patent medicine preparation.
Summary of the invention:
The object of the invention has provided the preparation method of WuBei dry mixed suspension, and this method comprises following
Step:
1., with Endoconcha Sepiae, Bulbus Fritillariae Thunbergii is beaten coarse powder, mixing sieves, and is standby.
2., above-mentioned coarse powder is broken into micropowder, to microscopically observation, particle diameter is at 1 to 25 micron, micropowder.
3., Oleum Citri Reticulatae is added micropowder, mixing.
4., to add pharmaceutic adjuvant an amount of, mixing, sterilization, packing is promptly.
The WuBei dry mixed suspension testing result that makes with the inventive method is as follows:
A. this product settling volume ratio should be not less than 0.9, should meet two oral solutions of the People's Republic of China's 2000 pharmacopeia, suspensoid, Emulsion item regulation down.
B. content uniformity: should meet two oral solutions of the People's Republic of China's 2000 pharmacopeia, suspensoid, Emulsion item regulation down.
C. loss on drying: should meet two oral solutions of the People's Republic of China's 2000 pharmacopeia, suspensoid, Emulsion item regulation down.
D. microbial limit: should meet two oral solutions of the People's Republic of China's 2000 pharmacopeia, suspensoid, Emulsion item regulation down.
Experimental example: Medicinal powder of cuttlefish and firtillary bulb powder, Medicinal powder of cuttlefish and firtillary bulb granule, Medicinal powder of cuttlefish and firtillary bulb dry suspension are to gastric ulcer rat therapeutical effect relatively.
Method and result: reserpine ulcer model.Get 60 of 18-22g Kunming kind white mice, male and female half and half are divided into 6 groups at random, 10 every group.Be respectively model group, Medicinal powder of cuttlefish and firtillary bulb powder (commercially available) 1.5g/kg group, Medicinal powder of cuttlefish and firtillary bulb granule (commercially available) 1.5g/kg group, Medicinal powder of cuttlefish and firtillary bulb dry suspension (self-control) basic, normal, high (0.75,1.5,3.0g/kg) dosage group.Each administration group gastric infusion every day 1 time, model group gives equal-volume distilled water, 20ml/kg.5d begins fasting (can't help water), after the 5th administration after the 4th administration continuously, subcutaneous injection of reserpine 10mg/Kg, after 1 hour under etherization, along the ventrimeson open abdomen, the ligation pylorus, each group is only injected relative medicine 1ml/ respectively immediately in duodenum, then skin suture.Water is prohibited in the fasting of postoperative animal, dislocation of cervical vertebra is put to death after 16 hours, opens the abdominal cavity, the ligation cardia, take out full stomach, immerse in 1% formalin, behind the 10min, cut off an osculum along greater gastric curvature and collect gastric juice and write down the gastric juice amount, then greater gastric curvature is cut open, open and flat on glass plate stomach, a situation arises to observe ulcer in gastric mucosa surface, and S=π d by formula
ld
s/ 4 (d
lRefer to longest diameter, d
sRefer to the shortest diameter) calculating ulcer area.Measure pH value, the pepsic activity of gastric juice.The results are shown in Table 1.
The anti-reserpine ulcer of table 1 Medicinal powder of cuttlefish and firtillary bulb different dosage form model test result (X ± s, n=10)
Dosage ulcer area gastric juice amount gastric acidity pepsin activity
Group
(g/kg) (mm
2) (ml) (pH) (μg/ml)
Model group 8.10 ± 2.81 5.93 ± 1.41 1.35 ± 0.54 168.1 ± 29.7
Powder group 1.50 4.89 ± 2.92
*4.46 ± 0.95
*3.06 ± 1.86
*129.9 ± 30.6
*
Granule group 1.50 5.10 ± 1.85
*4.55 ± 0.70
*3.10 ± 1.93
*130.8 ± 33.9
*
High dose group 3.00 2.56 ± 1.10
*3.29 ± 0.90
*5.76 ± 1.18
*106.5 ± 24.2
*
Middle dosage group 1.50 3.10 ± 1.06
*3.90 ± 0.68
*4.81 ± 1.21
*120.4 ± 30.1
*
Low dose group 0.75 5.12 ± 1.87
*4.62 ± 0.59
*2.99 ± 1.87
*135.1 ± 29.2
*
Annotate: compare with model group,
*P＜0.05;
*P＜0.01.
By table 1 as seen, the Medicinal powder of cuttlefish and firtillary bulb dry suspension than the secretion of granule, powder gastric acid inhibitory, reduce gastric acidity, to reduce the proteinase activity effect stronger, illustrate that Medicinal powder of cuttlefish and firtillary bulb is made dry suspension according to this technology after, be used for the treatment of gastric ulcer class disease, better efficacy.
Example 1, WuBei dry mixed suspension
Prescription: Endoconcha Sepiae 850g, Bulbus Fritillariae Thunbergii 150g, Oleum Citri Reticulatae 1.5g
Method: with Endoconcha Sepiae, Bulbus Fritillariae Thunbergii is beaten coarse powder, and mixing sieves, and again coarse powder is made micropowder, and to microscopically observation, mean diameter is at 5 to 25 microns; Oleum Citri Reticulatae is added micropowder, mixing.It is an amount of to add pharmaceutic adjuvant, mixing, and packing is promptly.
Example 2, the dried chewable tablet of Unio margarita
Method: with Endoconcha Sepiae, Bulbus Fritillariae Thunbergii is beaten coarse powder, and mixing sieves, and again coarse powder is made micropowder, and to microscopically observation, mean diameter is at 5 to 25 microns; Oleum Citri Reticulatae is added micropowder, mixing.It is an amount of to add pharmaceutic adjuvant, mixing, and tabletting, packing is promptly.
Claims (3)
1, a kind of WuBei dry mixed suspension is characterized in that on the present domestic Chinese patent medicine market and this medicine does not have dry suspension.Its preparation method is with Endoconcha Sepiae, and Bulbus Fritillariae Thunbergii is beaten coarse powder, and mixing sieves, and again coarse powder is made micropowder, and to microscopically observation, particle diameter is at 1 to 125 micron; Oleum Citri Reticulatae is added micropowder, mixing.Add right amount of auxiliary materials, mixing, sterilization, packing gained.
2, a kind of WuBei dry mixed suspension as claimed in claim 1 and preparation method thereof is characterized in that this method comprises the following steps:
1., with Endoconcha Sepiae, Bulbus Fritillariae Thunbergii is beaten coarse powder, mixing sieves, and is standby.
2., above-mentioned coarse powder is broken into micropowder, to microscopically observation, particle diameter is at 1 to 25 micron, micropowder.
3., Oleum Citri Reticulatae is added micropowder, mixing.
4., to add pharmaceutic adjuvant an amount of, mixing, sterilization, packing is promptly.
3, according to a kind of WuBei dry mixed suspension and the preparation method of claim 1 or 2, the preparation that it is characterized in that wherein said WuBei dry mixed suspension is by its preparation technology's gained.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410008194 CN1572309A (en) | 2003-06-05 | 2004-03-19 | Novel Chinese traditional medicine preparation of WuBei Powder for suspension and its preparation method |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03131673.5 | 2003-06-05 | ||
| CN03131673 | 2003-06-05 | ||
| CN 200410008194 CN1572309A (en) | 2003-06-05 | 2004-03-19 | Novel Chinese traditional medicine preparation of WuBei Powder for suspension and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1572309A true CN1572309A (en) | 2005-02-02 |
Family
ID=34523631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410008194 Pending CN1572309A (en) | 2003-06-05 | 2004-03-19 | Novel Chinese traditional medicine preparation of WuBei Powder for suspension and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1572309A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101491548B (en) * | 2008-12-26 | 2013-05-29 | 天津瑞普生物技术股份有限公司 | Suspension suitable for animal directly-drinking and preparation method thereof |
| CN105031354A (en) * | 2015-08-13 | 2015-11-11 | 重庆多普泰制药股份有限公司 | Unio margarita capsule used for curing gastroduodenal ulcer and preparation method and application of Unio margarita capsule |
| CN114404387A (en) * | 2022-01-18 | 2022-04-29 | 重庆多普泰制药股份有限公司 | A Bulbus Fritillariae Cirrhosae granule and its preparation method |
| CN114470092A (en) * | 2022-03-10 | 2022-05-13 | 徐英剑 | Pharmaceutical composition for treating upper gastrointestinal hemorrhage and powder thereof |
-
2004
- 2004-03-19 CN CN 200410008194 patent/CN1572309A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101491548B (en) * | 2008-12-26 | 2013-05-29 | 天津瑞普生物技术股份有限公司 | Suspension suitable for animal directly-drinking and preparation method thereof |
| CN105031354A (en) * | 2015-08-13 | 2015-11-11 | 重庆多普泰制药股份有限公司 | Unio margarita capsule used for curing gastroduodenal ulcer and preparation method and application of Unio margarita capsule |
| CN105031354B (en) * | 2015-08-13 | 2018-03-30 | 重庆多普泰制药股份有限公司 | Unio margarita capsule for treating gastroduodenal ulcer and its preparation method and application |
| CN114404387A (en) * | 2022-01-18 | 2022-04-29 | 重庆多普泰制药股份有限公司 | A Bulbus Fritillariae Cirrhosae granule and its preparation method |
| CN114470092A (en) * | 2022-03-10 | 2022-05-13 | 徐英剑 | Pharmaceutical composition for treating upper gastrointestinal hemorrhage and powder thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1128636C (en) | Pharmaceutical angiostatic dipeptide compositions and methods of use thereof | |
| WO2003068209A1 (en) | Metformin salts of lipophilic acids | |
| IL107255A (en) | Chewable pharmaceutical compositions containing ranitidine | |
| CN1919170A (en) | Colloid pectin bismuth dry suspensoid and its preparing process | |
| JPS60231617A (en) | Medicine composition for promoting cure of damaged digestivetract | |
| WO2024078507A1 (en) | Use of ergosterol in preparation of drug for preventing and treating gastric ulcers | |
| CN1572309A (en) | Novel Chinese traditional medicine preparation of WuBei Powder for suspension and its preparation method | |
| Morris et al. | Antacids and peptic ulcer--a reappraisal. | |
| CN114432425B (en) | Application of polypeptide in medicines for preventing and treating stomach diseases | |
| JPS60231618A (en) | Medicinal composition for promoting cure of gastro-intestinal tumor | |
| Venho et al. | Effect of gastric surgery on the gastrointestinal drug absorption in man | |
| CN1381259A (en) | Medicine for treating diseases of rectum and anus | |
| CN111317732A (en) | Pharmaceutical composition for preventing nephropathy of CT contrast agent and preparation method thereof | |
| KR0133998B1 (en) | Pharmaceutical composition for treating gastrointestinal | |
| RU2448728C1 (en) | METHOD OF PRE-OPERATION PREPARATION OF PATIENTS WITH ULCER DISEASE ASSOCIATED WITH Helicobacter pylori | |
| RU2252779C1 (en) | Method for preventing and treating ulcers of gastro-intestinal tract | |
| CN1883503A (en) | Pharmaceutical composition containing anti-ulcerative drug and mucosa-protecting agent for treating gastrosis | |
| CN114984004B (en) | Application of sulbactam sulfate in preparation of anti-sepsis medicine | |
| CN1297264C (en) | Loselofen sodium injection and its prepn | |
| JPH05504130A (en) | Tumor necrosis factor antagonist | |
| KR20050098831A (en) | Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist | |
| Segal et al. | A polyamine formaldehyde resin IV. Clinical evaluation in the treatment of duodenal ulcer | |
| CN113425713B (en) | Pharmaceutical composition for treating duodenal ulcer | |
| CN110585149A (en) | Preparation method and application of hydrotalcite combined medicine tablet | |
| CN116019809A (en) | Pharmaceutical composition for protecting gastric mucosa and treating gastric ulcer as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |